CoChat
Sign Up
Cited by 234

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Pegylated Liposomal Doxorubicin: A Review of its use in Metastatic Breast Cancer, Ovarian Cancer, Multiple Myeloma and AIDS-Related Kaposiʼs Sarcoma

Duggan, Sean T., Keating, Gillian M.·2011·Drugs
DOI 10.2165/11207510-000000000-00000
Open this paper in CoChat — free account

Abstract

Pegylated liposomal doxorubicin (Caelyx™, Doxil®) represents an improved formulation of conventional doxorubicin, with reduced cardiotoxicity and an improved pharmacokinetic profile. This article reviews the efficacy and tolerability of pegylated liposomal doxorubicin in metastatic breast cancer, progressive ovarian cancer, relapsed or refractory multiple myeloma and AIDS-related Kaposi's sarcoma, as well as summarizing its pharmacological properties. In three randomized, open-label, multicentre trials, monotherapy with pegylated liposomal doxorubicin was as effective as doxorubicin or capecitabine in the first-line treatment of metastatic breast cancer, and as effective as vinorelbine or combination mitomycin plus vinblastine in taxane-refractory metastatic breast cancer. Pegylated liposomal doxorubicin alone was as effective as topotecan or gemcitabine alone in patients with progressive ovarian cancer resistant or refractory to platinum- or paclitaxel-based therapy, according to the results of three randomized multicentre trials. In addition, in patients with progressive ovarian cancer who had received prior platinum-based therapy, progression-free survival was significantly longer with pegylated liposomal doxorubicin plus carboplatin than with paclitaxel plus carboplatin, according to the results of a randomized, open-label multicentre trial. Combination therapy with pegylated liposomal doxorubicin plus bortezomib was more effective than bortezomib alone in patients with r…

Overview

Integrity signals

Registry

Crossref · 10.2165/11207510-000000000-00000

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 2 references

Research works printed but not linked: 84

  1. OʼBrien, 2004, Ann Oncol, 15, 440, 10.1093/annonc/mdh097 · DOI
  2. Safra, 2003, Oncologist, 8, 17, 10.1634/theoncologist.8-suppl_2-17 · DOI
  3. Dando, 2005, Am J Cancer, 4, 193, 10.2165/00024669-200504030-00006 · DOI
  4. Plosker, 2008, Drugs, 68, 2535, 10.2165/0003495-200868170-00008 · DOI
  5. Sharpe, 2002, Drugs, 62, 2089, 10.2165/00003495-200262140-00012 · DOI
  6. Coukell, 1997, Drugs, 53, 520, 10.2165/00003495-199753030-00011 · DOI
  7. Pignata, 2011, J Clin Oncol, 29, 3628, 10.1200/JCO.2010.33.8566 · DOI · Paper page
  8. Minotti, 2004 Jun, Pharmacol Rev, 56, 185, 10.1124/pr.56.2.6 · DOI
  9. Vail, 2004, Semin Oncol, 31, 16, 10.1053/j.seminoncol.2004.08.002 · DOI
  10. Voorhees, 2007 Apr, Clin Lymphoma Myeloma, 7, S156, 10.3816/CLM.2007.s.017 · DOI
  11. Small, 2003, J Pharmacol Exp Ther, 307, 861, 10.1124/jpet.103.055806 · DOI
  12. Small, 2004, Mol Pharmacol, 66, 1478, 10.1124/mol.104.003400 · DOI
  13. Sturzl, 1994, Res Virol, 145, 261, 10.1016/S0923-2516(07)80031-8 · DOI
  14. Gabizon, 2003, Clin Pharmacokinet, 42, 419, 10.2165/00003088-200342050-00002 · DOI
  15. Orlowski, 2005, Blood, 105, 3058, 10.1182/blood-2004-07-2911 · DOI
  16. Zamboni, 2008 Mar, Oncologist, 13, 248, 10.1634/theoncologist.2007-0180 · DOI
  17. Gabizon, 1994 Feb 15, Cancer Res, 54, 987
  18. Richly, 2009, Int J Clin Pharmacol Ther, 47, 55, 10.5414/CPP47055 · DOI
  19. Gabizon, 2008 Apr, Cancer Chemother Pharmacol, 61, 695, 10.1007/s00280-007-0525-5 · DOI
  20. Cattel, 2006, Anticancer Res, 26, 745
  21. Keller, 2004 Oct 1, J Clin Oncol, 22, 3893, 10.1200/JCO.2004.08.157 · DOI
  22. Alba, 2010 Jul, Breast Cancer Res Treat, 122, 169, 10.1007/s10549-010-0860-9 · DOI
  23. Ferrandina, 2008 Feb 20, J Clin Oncol, 26, 890, 10.1200/JCO.2007.13.6606 · DOI
  24. Gordon, 2001 Jul 15, J Clin Oncol, 19, 3312, 10.1200/JCO.2001.19.14.3312 · DOI
  25. Mutch, 2007 Jul 1, J Clin Oncol, 25, 2811, 10.1200/JCO.2006.09.6735 · DOI
  26. Pujade-Lauraine, 2010 Jul 10, J Clin Oncol, 28, 3323, 10.1200/JCO.2009.25.7519 · DOI
  27. Gordon, 2004 Oct, Gynecol Oncol, 95, 1, 10.1016/j.ygyno.2004.07.011 · DOI
  28. Colombo, 2010, Ann Oncol, 21, v23, 10.1093/annonc/mdq244 · DOI
  29. Poveda, 2011, Ann Oncol, 22, 39, 10.1093/annonc/mdq352 · DOI
  30. Orlowski, 2007 Sep 1, J Clin Oncol, 25, 3892, 10.1200/JCO.2006.10.5460 · DOI
  31. Blade, 2011 Feb, Clin Lymphoma Myeloma Leuk, 11, 44, 10.3816/CLML.2011.n.005 · DOI
  32. Blade, 2008, Clin Lymphoma Myeloma, 8, 352, 10.3816/CLM.2008.n.051 · DOI
  33. Sonneveld, 2008 Apr 1, Cancer, 112, 1529, 10.1002/cncr.23326 · DOI
  34. Harousseau, 2009, Ann Oncol, 20, ii97, 10.1093/annonc/mdp140 · DOI
  35. Blade, 2008, Ann Oncol, 19, vii117, 10.1093/annonc/mdn437 · DOI
  36. Cianfrocca, 2010 Aug 15, Cancer, 116, 3969, 10.1002/cncr.25362 · DOI
  37. Northfelt, 1998 Jul, J Clin Oncol, 16, 2445, 10.1200/JCO.1998.16.7.2445 · DOI
  38. Stewart, 1998 Feb, J Clin Oncol, 16, 683, 10.1200/JCO.1998.16.2.683 · DOI
  39. Martin-Carbonero, 2004 Aug 20, AIDS, 18, 1737, 10.1097/01.aids.0000131385.60974.b9 · DOI
  40. Krown, 1989 Sep, J Clin Oncol, 7, 1201, 10.1200/JCO.1989.7.9.1201 · DOI
  41. Osoba, 2001, Cancer Invest, 19, 573, 10.1081/CNV-100104284 · DOI
  42. Hengge, 2001 May, Eur J Cancer, 37, 878, 10.1016/S0959-8049(01)00053-3 · DOI
  43. Sehouli, 2006 Jun, Ann Oncol, 17, 957, 10.1093/annonc/mdl079 · DOI
  44. Lorusso, 2004, Oncology, 67, 243, 10.1159/000081324 · DOI
  45. Al-Batran, 2006, Oncology, 70, 141, 10.1159/000093005 · DOI
  46. Markman, 2000 Sep, Gynecol Oncol, 78, 369, 10.1006/gyno.2000.5921 · DOI
  47. Tanyi, 2009 Aug, Gynecol Oncol, 114, 219, 10.1016/j.ygyno.2009.04.007 · DOI
  48. Kim, 2005, Gynecol Oncol, 97, 374, 10.1016/j.ygyno.2004.12.057 · DOI
  49. Rose, 2001 Aug, Gynecol Oncol, 82, 323, 10.1006/gyno.2001.6272 · DOI
  50. von Moos, 2008, Eur J Cancer, 44, 781, 10.1016/j.ejca.2008.01.028 · DOI
  51. Kesterson, 2010, Chemotherapy, 56, 108, 10.1159/000312644 · DOI
  52. Yildirim, 2008, Int J Gynecol Cancer, 18, 223, 10.1111/j.1525-1438.2007.00992.x · DOI
  53. Lichterfeld, 2005 Jun, Infection, 33, 140, 10.1007/s15010-005-4099-z · DOI
  54. OʼBrien, 2008 Jan, Anticancer Drugs, 19, 1, 10.1097/CAD.0b013e3282f14a00 · DOI
  55. Lyass, 2000 Sep 1, Cancer, 89, 1037, 10.1002/1097-0142(20000901)89:5<1037::AID-CNCR13>3.0.CO;2-Z · DOI
  56. Rose, 2005 Mar, Oncologist, 10, 205, 10.1634/theoncologist.10-3-205 · DOI
  57. Shimada, 2011, J Clin Oncol, 29, Suppl, 10.1200/jco.2011.29.4_suppl.621 · DOI
  58. Martschick, 2009 Jun, Anticancer Res, 29, 2307
  59. Cannistra, 2010 Jul 1, J Clin Oncol, 28, 3101, 10.1200/JCO.2010.29.7077 · DOI
  60. Ferlay, 2010, Int J Cancer, 127, 2893, 10.1002/ijc.25516 · DOI
  61. Cardoso, 2010, Ann Oncol, 21, v15, 10.1093/annonc/mdq160 · DOI
  62. Gennari, 2011 Jun, J Clin Oncol, 29, 2144, 10.1200/JCO.2010.31.5374 · DOI
  63. OʼShaughnessy, 2005, Oncologist, 10, 20, 10.1634/theoncologist.10-90003-20 · DOI
  64. Sparano, 2009 Sep 20, J Clin Oncol, 27, 4522, 10.1200/JCO.2008.20.5013 · DOI
  65. Wolff, 2010 May, Breast Cancer Res Treat, 121, 111, 10.1007/s10549-010-0838-7 · DOI
  66. de la Fouchardiere, 2009, Ann Oncol, 20, 1959, 10.1093/annonc/mdp231 · DOI
  67. Christodoulou, 2009, Oncology, 76, 275, 10.1159/000207504 · DOI
  68. Chia, 2006 Jun 20, J Clin Oncol, 24, 2773, 10.1200/JCO.2005.03.8331 · DOI
  69. Mlineritsch, 2009, Onkologie, 32, 18, 10.1159/000180915 · DOI
  70. Livi, 2011, J Chemother, 23, 158, 10.1179/joc.2011.23.3.158 · DOI
  71. Vorobiof, 2004, Breast, 13, 219, 10.1016/j.breast.2004.01.006 · DOI
  72. Gogas, 2002, Ann Oncol, 13, 1737, 10.1093/annonc/mdf284 · DOI
  73. Rossi, 2008, Anticancer Drugs, 19, 733, 10.1097/CAD.0b013e3283043585 · DOI
  74. Manente, 2010, J Clin Oncol, 28, Suppl, 10.1200/jco.2010.28.15_suppl.e11097 · DOI
  75. Elsaid, 2010, J Clin Oncol, 28, Suppl, 10.1200/jco.2010.28.15_suppl.e11050 · DOI
  76. Liu, 2010 Jul, Oncology (Williston Park), 24, 721
  77. Muggia, 2011 Jan 19, J Natl Cancer Inst, 103, 160, 10.1093/jnci/djq484 · DOI
  78. Ferlay, 2010 Mar, Eur J Cancer, 46, 765, 10.1016/j.ejca.2009.12.014 · DOI
  79. Ludwig, 2007, Ann Oncol, 18, ix64, 10.1093/annonc/mdm296 · DOI
  80. Richardson, 2010, Oncology (Williston Park), 24, 22
  81. Buda, 2010, Ann Hematol, 89, 1133, 10.1007/s00277-010-0992-3 · DOI
  82. Udhrain, 2007, Int J Nanomed, 2, 345, 10.2217/17435889.2.3.345 · DOI
  83. Hengge, 2004, Am J Cancer, 3, 133, 10.2165/00024669-200403030-00001 · DOI
  84. Bower, 2008, HIV Med, 9, 336, 10.1111/j.1468-1293.2008.00608.x · DOI

Cited by

Sorted by citations

See all 234

Metadata

Authors
Duggan, S. T., & Keating, G. M.
Venue
Drugs
Publisher
Springer Science and Business Media LLC
Published
2011-12
Volume
71
Issue
18
Pages
2531-2558
ISSN
0012-6667
DOI
10.2165/11207510-000000000-00000
Cited by
234
References
2
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review